Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections

Schunter, Marco; Walles, Thorsten; Fritz, Péter; Meyding‐Lamadé, Uta; Thon, Klaus‐Peter; Fellermann, Klaus; Stange, Eduard F.; Lamadé, Wolfram

doi:10.1016/j.crohns.2007.06.004

Cited by 26 publications

(33 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4,28–42] Almost all of the cases occurred in immunocompromised hosts, nearly a third (n = 5) of whom were receiving corticosteroid therapy for IBD (Table 2). [4,33,39,41,42] In contrast, CMV is routinely implicated as an intestinal pathogen in patients with IBD. Indeed, among patients with IBD presenting with acute colitis, reported prevalence rates of CMV infection have ranged from 21% to 34%, and in those with steroid-refractory disease it can be as high 36%.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, among patients with IBD presenting with acute colitis, reported prevalence rates of CMV infection have ranged from 21% to 34%, and in those with steroid-refractory disease it can be as high 36%. [1] As is the case for CMV, HSV colitis in this population often mimics the underlying disease, presenting as fever, abdominal pain and diarrhea, rectal bleeding, [4,39,42] or even paralytic ileus, [41] generally in the absence of suggestive mucocutaneous involvement. Endoscopic findings may be nonspecific and can include edema, erythema sometimes with petechiae, and well-demarcated ulcers of variable size and depth with or without purulent exudate, often separated by normal-appearing mucosa.…”

Section: Discussionmentioning

confidence: 99%

“…Endoscopic findings may be nonspecific and can include edema, erythema sometimes with petechiae, and well-demarcated ulcers of variable size and depth with or without purulent exudate, often separated by normal-appearing mucosa. [41,42] …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis

et al. 2016

View full text Add to dashboard Cite

Background:Herpesvirus infections often complicate the clinical course of patients with inflammatory bowel disease; however, invasive disease due to herpes simplex virus is distinctly uncommon.Methods:We present a case of herpes simplex virus colitis and hepatitis, review all the previously published cases of herpes simplex virus colitis, and discuss common clinical features and outcomes. We also discuss the epidemiology, clinical manifestations, diagnosis, and management of herpes simplex virus infections, focusing specifically on patients with inflammatory bowel disease.Results:A 43-year-old man with ulcerative colitis, previously controlled with an oral 5-aminosalicylic agent, developed symptoms of a colitis flare that did not respond to treatment with systemic corticosteroid therapy. One week later he developed orolabial ulcers and progressive hepatic dysfunction, with markedly elevated transaminases and coagulopathy. He underwent emergent total colectomy when imaging suggested bowel micro-perforation. Pathology from both the colon and liver was consistent with herpes simplex virus infection, and a viral culture of his orolabial lesions and a serum polymerase chain reaction assay also identified herpes simplex virus. He was treated with systemic antiviral therapy and made a complete recovery.Conclusions:Disseminated herpes simplex virus infection with concomitant involvement of the colon and liver has been reported only 3 times in the published literature, and to our knowledge this is the first such case in a patient with inflammatory bowel disease. The risk of invasive herpes simplex virus infections increases with some, but not all immunomodulatory therapies. Optimal management of herpes simplex virus in patients with inflammatory bowel disease includes targeted prophylactic therapy for patients with evidence of latent infection, and timely initiation of antiviral therapy for those patients suspected to have invasive disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…TST and QFT-TB Gold/QFT-TB Gold In-Tube had a rate of uniformity of 85% (95%CI: 77-90), while the conformity of TST and T-SPOT.TB was 72% (95%CI: [64][65][66][67][68][69][70][71][72][73][74][75][76][77][78]. A relevant problem in interpreting these results is the occurrence of indeterminate test.…”

Section: Mycobacterium Tuberculosismentioning

confidence: 99%

“…In immunocompromised patients, herpes simplex virus (HSV) infection may cause severe disseminate infection of different organs (including encephalitis, meningitis, pneumonia, gastrointestinal infection, and hepatitis) [78,79] . Diagnosis of HSV infection is generally suspected based on clinical findings.…”

Section: Herpes Simplex Virusmentioning

confidence: 99%

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Andrisani

Armuzzi

Marzo

et al. 2016

WJGPT

View full text Add to dashboard Cite

increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review. Core tip: The increasing use of biologics as a mainstay of therapy in inflammatory bowel disease (IBD) is associated with an increased risk for a variety of infections, many of which are preventable by prior screening and vaccination. While immunocompetent IBD patients can be vaccinated using standard vaccination schedule, special guidelines need to be followed for IBD patients getting immunosuppressive therapy (IST). This article provides a review of the issues surrounding immunizations in the IBD patient and a practical guide for clinicians regarding the appropriate screening for infections and vaccinations to administer both before and during IST. AbstractThe use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an REVIEWSubmit a

show abstract

Integrative analysis of transcriptome‐wide association study data and messenger RNA expression profiles identified candidate genes and pathways for inflammatory bowel disease

Cheng

Liang

Wen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a complex disease, resulting from abnormal immune response to intestinal tract microbiota in genetically susceptible individuals. Crohn's disease and ulcerative colitis (UC) are the two major types of IBD. Transcriptome‐wide association study (TWAS) of IBD was first performed using a large‐scale genome‐wide association study summary data sets of IBD. The FUSION software was applied for TWAS, considering various tissues and cells. The genes identified by TWAS were then validated by the gene expression profiling data sets of IBD. The functional annotation and potential pathways of common differentially expressed genes were further subjected to gene ontology (GO) and pathway enrichment analysis. Integrative analysis of TWAS and messenger RNA (mRNA) expression data detected several tissues related common genes for UC, such as HLA‐DRB1 (PTWAS = 0.024; mRNA expression ratio = 1.700) and TAP2 in colon (P TWAS = 0.047; mRNA expression ratio = 2.170). Further comparing the GO enrichment analysis results of TWAS and mRNA expression data, we identified 11 common GO terms for UC, such as plasma membrane (P value = 5.08 × 10−10) in intestinal tissues and immune response (P = 0.001) in peripheral blood. We also detected several common pathways for UC, including cell adhesion molecules (P = 0.003) in intestinal tissues, IBD (P = 0.049) in whole blood and phagosome (P = 0.0003) in peripheral blood. Our study results provide novel clues for understanding the genetic mechanism of IBD.

show abstract

Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections

Cited by 26 publications

References 44 publications

Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis

Concomitant herpes simplex virus colitis and hepatitis in a man with ulcerative colitis

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Integrative analysis of transcriptome‐wide association study data and messenger RNA expression profiles identified candidate genes and pathways for inflammatory bowel disease

Contact Info

Product

Resources

About